FDAapproval65% confidence
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer
Source: FDA
Why This Matters
Why this matters: sets a approval precedent in the same sub-indication (liver cancer) as AstraZeneca.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Hepatocellular Carcinoma
- Sub-indication
- Liver Cancer
Related signal: AstraZeneca's Study on Durvalumab and Tremelimumab in HCC with TACE